^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:PD-L1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases.

    Published date:
    05/13/2020
    Excerpt:
    ...In multivariate Cox regression analysis, active BM, poor PS and EGFR..(+) were selected as significant factors associated with poor PFS….Anti-PD-(L)1 monotherapy is not recommend for pts with active BMs.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e14511